

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
and a Waiver under 21 U.S.C. §355 (n)(4)

James L. Omel, M.D.

Committee: Anti-Infective Drugs Advisory Committee

Meeting Date: March 6, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to New Drug Application (NDA) 21-572/S-008, Cubicin (daptomycin for injection 500 mg/vial), manufactured for Cubist Pharmaceuticals by Integrated Commercialization Solutions, for the proposed indication for the treatment of Staphylococcus aureus bacteremia, including those with known or suspected endocarditis caused by methicillin-susceptible and methicillin-resistant strains, I am eligible to receive a waiver under 21 U.S.C. §355 (n)(4).

Type of Interest	Nature	Magnitude
Stock	Competitor	Valued at less than \$5,001

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

//s//
Signature of SGE

1-27-06
Date